CG Oncology (NASDAQ:CGON) Director James Mulay Sells 1,964 Shares of Stock

CG Oncology, Inc. (NASDAQ:CGON) Director James Mulay sold 1,964 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $60.12, for a total transaction of $118,075.68. Following the completion of the sale, the director owned 654 shares of the company’s stock, valued at approximately $39,318.48. The trade was a 75.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Mulay also recently made the following trade(s):

• On Friday, April 17th, James Mulay sold 15,600 shares of CG Oncology stock. The stock was sold at an average price of $73.01, for a total transaction of $1,138,956.00.

CG Oncology Price Performance

NASDAQ CGON opened at $60.28 on Wednesday. CG Oncology, Inc. has a 1 year low of $23.65 and a 1 year high of $75.50. The firm has a market cap of $5.32 billion, a price-to-earnings ratio of -25.87 and a beta of 0.31. The company has a fifty day moving average price of $64.74 and a 200-day moving average price of $56.84.

CG Oncology (NASDAQ:CGON) last posted its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The firm had revenue of $1.08 million for the quarter, compared to analysts’ expectations of $0.45 million. On average, research analysts anticipate that CG Oncology, Inc. will post -2.89 EPS for the current fiscal year.

Analyst Ratings Changes

CGON has been the topic of a number of research analyst reports. JPMorgan Chase & Co. boosted their price target on shares of CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Truist Financial reissued a “buy” rating and issued a $82.00 price target (up from $77.00) on shares of CG Oncology in a report on Thursday, May 14th. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of CG Oncology in a report on Monday, May 18th. Royal Bank Of Canada boosted their price target on shares of CG Oncology from $79.00 to $81.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Finally, Wolfe Research initiated coverage on shares of CG Oncology in a report on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.73.

Institutional Investors Weigh In On CG Oncology

Several institutional investors have recently added to or reduced their stakes in the business. NFSG Corp purchased a new stake in CG Oncology during the first quarter valued at about $34,000. Comerica Bank lifted its holdings in CG Oncology by 100.4% during the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after purchasing an additional 515 shares during the last quarter. LPL Financial LLC lifted its holdings in CG Oncology by 9.8% during the fourth quarter. LPL Financial LLC now owns 6,201 shares of the company’s stock valued at $257,000 after purchasing an additional 551 shares during the last quarter. Whittier Trust Co. of Nevada Inc. purchased a new stake in CG Oncology during the fourth quarter valued at about $27,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in CG Oncology by 33.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company’s stock valued at $163,000 after purchasing an additional 972 shares during the last quarter. 26.56% of the stock is owned by hedge funds and other institutional investors.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.